Orencia

Phase 1Small molecule

Bristol-Myers Squibb

Orencia is one of 50 small molecule programs targeting Autoimmune Hepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune HepatitisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Autoimmune HepatitisPhase 1

Active, not recruiting

Rheumatoid ArthritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Actemra

Enbrel

64 4

Remicade

OOrganon and Co

Preclinical

43 5

Arcoxia

Novartis

Preclinical

4 6

Actos

Takeda

Preclinical

2 7

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 10

Certolizumab

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis5 trials

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Completed·MMedical University of Vienna·Phase 4·NCT01638715·115 enrolled

Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

Unknown status·KKarolinska Institutet·Phase 4·NCT01491815·812 enrolled

Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02758769·303 enrolled

Show 2 more trials

Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

Unknown status·KKarolinska Institutet·Phase 4·NCT02466581·25 enrolled

Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01694693

Autoimmune Hepatitis1 trial

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Terminated·SStuart Knechtle, M.D.·Phase 1·NCT04203875·1 enrolled

Intravenous1 trial

Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02600468·671 enrolled

Sjogren's Syndrome1 trial

Sjogrens Syndrome Measured by Ultrasound

Unknown status·AArthritis & Rheumatism Associates, P.C.·Phase 2·NCT03411850·20 enrolled

Unspecified1 trial

Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02600455·505 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Orencia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orencia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orencia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bristol-Myers Squibb

Orencia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis5 trials

Autoimmune Hepatitis1 trial

Intravenous1 trial

Sjogren's Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News